

TEXTBOOK OF

Pharmacoepidemiology

SECOND EDITION

Edited by
Brian L. Strom
Stephen E. Kimmel
Sean Hennessy

WILEY Blackwell

Contents

[Cover](#)

[Title Page](#)

[Copyright](#)

[Contributors](#)

[Preface](#)

[Acknowledgements](#)

[Part I: Introduction to Pharmacoepidemiology.](#)

[Chapter 1: What is Pharmacoepidemiology?](#)

[Introduction](#)

[Definition of Pharmacoepidemiology.](#)

[Historical Background](#)

[The Current Drug Approval Process](#)

[Potential Contributions of Pharmacoepidemiology.](#)

[Key Points](#)

[Further Reading](#)

Chapter 2: Study Designs Available for Pharmacoepidemiologic Studies

Overview of the Scientific Method

Types of Errors that One can Make in Performing a Study

Criteria for the Causal Nature of an Association

Epidemiologic Study Designs

Case Reports

Conclusion

Key Points

Further Reading

Chapter 3: Sample Size Considerations for Pharmacoepidemiologic Studies

Introduction

Sample Size Calculations for Cohort Studies

Sample Size Calculations for Case-Control Studies

Sample Size Calculations for Case Series

Discussion

Key Points

References and Further Readings

Chapter 4: Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies

Clinical Pharmacology and Pharmacoepidemiology

Basics of Clinical Pharmacology

[Pharmacokinetics](#)
[Special Populations](#)
[Pharmacodynamics](#)
[Pharmacogenomics](#)
[Conclusion](#)
[Key Points](#)
[Further Reading](#)

[Chapter 5: When Should One Perform Pharmacoepidemiologic Studies?](#)

[Reasons to Perform Pharmacoepidemiologic Studies](#)
[Safety versus Risk](#)
[Risk Tolerance](#)
[Conclusion](#)
[Key Points](#)
[Further Reading](#)

[Chapter 6: Views from Academia, Industry, Regulatory Agencies, and the Legal System](#)

[The View from Academia](#)
[Summary Points for the View from Academia](#)
[The View from Industry](#)
[The View from Regulatory Agencies](#)
[The View from the Legal System](#)
[Further Reading](#)

Part II: Sources of Pharmacoepidemiology Data

Chapter 7: Postmarketing Spontaneous Pharmacovigilance Reporting Systems

Introduction

Description

Strengths

Limitations

Particular Applications

The Future

Key Points

Further Reading

Chapter 8: Overview of Automated Databases in Pharmacoepidemiology

Introduction

Description

Strengths

Weaknesses

Particular Applications

The Future

Key Points

Further Reading

Chapter 9: Examples of Existing Automated Databases

[US Health Maintenance Organizations/Health Plans](#)

[US Government Claims Databases](#)

[Canadian Provincial Databases](#)

[Medical Record Databases](#)

[Pharmacy-Based Medical Record Linkage Systems](#)

[Further Reading](#)

[Chapter 10: Field Studies](#)

[Strengths](#)

[Weaknesses](#)

[Particular Applications](#)

[Conclusions](#)

[Key Points](#)

[Further Reading](#)

[Chapter 11: How Should One Perform Pharmacoepidemiologic Studies? Choosing Among the Available Alternatives](#)

[Introduction](#)

[Choosing Among the Available Approaches to Pharmacoepidemiologic Studies](#)

[Examples](#)

[Conclusion](#)

[Key Points](#)

[Further Reading](#)

Part III: Special Issues in Pharmacoepidemiology Methodology.

Chapter 12: Validity of Pharmacoepidemiologic Drug and Diagnosis Data

Introduction

Clinical Problems to be Addressed by
Pharmacoepidemiologic Research

Methodological Problems to be Solved by
Pharmacoepidemiologic Research

Methodological Problems in
Pharmacoepidemiologic Research

Currently Available Solutions

The Future

Key Points

Further Reading

Chapter 13: Assessing Causality of Case Reports of Suspected Adverse Events

Introduction

Clinical Problems to be Addressed by
Pharmacoepidemiologic Research

Historical Perspectives: Development of Concepts

Uses of Causality Assessment

Methodological Problems to be Addressed by
Pharmacoepidemiologic Research

[Current Tools](#)

[Unstructured Clinical Judgment/Global](#)

[Introspection](#)

[Algorithm/Criterial Method with Verbal Judgments](#)

[Algorithms Requiring Scoring of Individual Judgments](#)

[Probabilistic Methods](#)

[Comparison Among the Different Methods](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

[Chapter 14: Molecular Pharmacoepidemiology](#)

[Introduction](#)

[Definitions and Concepts](#)

[The Interface of Pharmacogenetics and Pharmacogenomics with Molecular Pharmacoepidemiology](#)

[Clinical Problems to be Addressed by Pharmacoepidemiologic Research](#)

[Three Ways that Genes can Affect Drug Response](#)

[The Progression and Application of Molecular Pharmacoepidemiologic Research](#)

[Methodological Problems to be Addressed by Pharmacoepidemiologic Research](#)

[Currently Available Solutions](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

Chapter 15: Bioethical Issues in Pharmacoepidemiologic Research

Introduction

Clinical Problems to be Addressed by Pharmacoepidemiologic Research

Methodological Problems to be Addressed by Pharmacoepidemiologic Research

Currently Available Solutions

Conclusion

Key Points

Further Reading

Chapter 16: The Use of Randomized Controlled Trials for Pharmacoepidemiologic Studies

Introduction

Clinical Problems to be Addressed by Pharmacoepidemiologic Research

Methodological Problems to be Solved by Pharmacoepidemiologic Research

Currently Available Solutions

The Future

Key Points

Further Reading

Chapter 17: Pharmacoeconomics: Economic Evaluation of Pharmaceuticals

Clinical Problems to be Addressed by Pharmacoeconomic Research

[Economic Evaluation and the Drug Development Process](#)

[Methodological Problems to be Addressed by Pharmacoeconomic Research](#)

[Methodological Issues in the Pharmacoeconomic Assessment of Therapies](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

[Chapter 18: Using Quality-of-Life Measurements in Pharmacoepidemiologic Research](#)

[Introduction](#)

[Clinical Problems to be Addressed by Pharmacoepidemiologic Research](#)

[Methodological Problems to be Addressed by Pharmacoepidemiologic Research](#)

[Currently Available Solutions](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

[Chapter 19: The Use of Meta-analysis in Pharmacoepidemiology](#)

[Introduction](#)

[Clinical Problems to be Addressed by Pharmacoepidemiologic Research](#)

[Methodological Problems to be Addressed by
Pharmacoepidemiologic Research](#)
[Currently Available Solutions](#)
[Currently Available Solutions](#)
[The Future](#)
[Key Points](#)
[Further Reading](#)

[Chapter 20: Studies of Medication Adherence](#)

[Introduction](#)
[Clinical Problems to be Addressed by
Pharmacoepidemiologic Research](#)
[Methodologic Problems to be Solved by
Pharmacoepidemiologic Research](#)
[Currently Available Solutions](#)
[Future Directions](#)
[Key Points](#)
[Further Reading](#)

[Chapter 21: Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies](#)

[Clinical Problems to be Addressed by
Pharmacoepidemiologic Research](#)
[Methodological Problems to be Addressed by
Pharmacoepidemiologic Research](#)
[Currently Available Solutions](#)
[Conclusion](#)

[Key Points](#)

[Further Reading](#)

[Part IV: Special Applications](#)

[Chapter 22: Special Applications of Pharmacoepidemiology](#)

[Studies of Drug Utilization](#)

[Evaluating and Improving Physician Prescribing](#)

[Special Methodological Issues in](#)

[Pharmacoepidemiologic Studies of Vaccine Safety](#)

[Key Points for Special Methodological Issues in](#)

[Pharmacoepidemiologic Studies of Vaccine Study](#)

[Epidemiologic Studies of Implantable Medical](#)

[Devices](#)

[Studies of Drug-Induced Birth Defects](#)

[Risk Management](#)

[The Use of Pharmacoepidemiology to Study](#)

[Medication Errors](#)

[FDA's Sentinel Initiative: Enhancing Safety](#)

[Surveillance](#)

[Comparative Effectiveness Research](#)

[Further Reading](#)

[Chapter 23: The Future of Pharmacoepidemiology](#)

[The View from Academia](#)

[The View from Industry](#)

[The View from Regulatory Agencies](#)

[The View from the Law](#)

[Conclusion](#)

[Key Points](#)

[Further Reading](#)

[Appendix A: Sample Size Tables](#)

[Appendix B: Glossary](#)

[Index](#)

Textbook of Pharmacoepidemiology

EDITED BY

Brian L. Strom, MD, MPH

Executive Vice Dean for Institutional Affairs
George S. Pepper Professor of Public Health and Preventive Medicine, Professor of Biostatistics and
Epidemiology, of Medicine, and of Pharmacology
Center for Clinical Epidemiology and Biostatistics
Center for Pharmacoepidemiology Research and Training
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
USA

Stephen E. Kimmel, MD, MSCE

Professor of Medicine and of Epidemiology
Center for Clinical Epidemiology and Biostatistics
Center for Pharmacoepidemiology Research and Training
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
USA

Sean Hennessy, PharmD, PhD

Associate Professor of Epidemiology and of Pharmacology
Center for Clinical Epidemiology and Biostatistics
Center for Pharmacoepidemiology Research and Training
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
USA

SECOND EDITION

WILEY Blackwell

This edition first published 2013 © 2013 by John Wiley & Sons Ltd

First Edition published 2006 by John Wiley & Sons Ltd.

Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley's global Scientific, Technical and Medical business with Blackwell Publishing.

Registered office: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the

understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Textbook of pharmacoepidemiology / edited by Brian L. Strom, Stephen E. Kimmel, Sean Hennessy. – 2nd ed.

p. ; cm.

Abridged version of: Pharmacoepidemiology. 5th ed. 2012.

Includes bibliographical references and index.

ISBN 978-1-118-34486-6 (pbk. : alk. paper)

I. Strom, Brian L. II. Kimmel, Stephen E. III. Hennessy, Sean. IV. Pharmacoepidemiology.

[DNLM: 1. Pharmacoepidemiology–methods. QZ 42]

RM302.5

615.7'042–dc23

2013002833

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image: iStock © FotografiaBasica, Karina Tischlinger

Cover design by Rob Sawkins for Opta Design

Contributors

Trisha Acri

Formerly, Assistant Professor
of Family and Community Medicine
Temple University School of Medicine
Philadelphia, PA Currently, Director of Community Research
Health Services
AIDS Care Group
Sharon Hill, PA
USA

Susan E. Andrade

Senior Research Associate and
Research Associate Professor
Meyers Primary Care Institute
and
University of Massachusetts Medical School
Worcester, MA
USA

Peter Arlett

Head
Pharmacovigilance and Risk
Management
European Medicines Agency
London, UK

Jerry Avorn

Professor of Medicine
Harvard Medical School
and
Chief

Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital
Boston, MA
USA

Jeffrey S. Barrett

Director
Laboratory for Applied Pharmacokinetics and
Pharmacodynamics
Director
Pediatric Pharmacology Research Unit
The Children's Hospital of Philadelphia
Research Professor of Pediatrics
Kinetic Modeling and Simulation (KMAS) Core Director
Perelman School of Medicine at the University of
Pennsylvania
Colket Translational Research
Philadelphia, PA
USA

David W. Bates

Division of General Internal Medicine and Primary Care
Brigham and Women's Hospital
and
Harvard Medical School
Boston, Massachusetts
USA

Jesse A. Berlin

Vice President
Epidemiology
Janssen Research & Development, LLC
Johnson & Johnson
Titusville, NJ
USA

Stella Blackburn

EMA Risk Management Development
and Scientific Lead
European Medicines Agency
London, UK

Denise M. Boudreau

Scientific Investigator
Group Health Research Institute
Seattle, WA
USA

M. Soledad Cepeda

Director
Epidemiology
Janssen Research & Development, LLC
Johnson & Johnson
Titusville, NJ
USA

Robert T. Chen

Medical Officer
Clinical Trials Team
Epidemiology Branch
Division of HIV/AIDS Prevention
Centers for Disease Control and Prevention
Atlanta, GA
USA

Francesca Cunningham

Director
Center for Medication Safety
and
Program Manager
Outcomes Research PBM Services
Department of Veterans Affairs

Center for Medication Safety
Hines, IL
USA

Gerald J. Dal Pan

Director
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
US Food and Drug Administration
Silver Spring, MD
USA

Hassy Dattani

Research Director (retired)
Cegecim Strategic Data Medical
Research Ltd
London, UK

Robert L. Davis

Director of Research
Center for Health Research
Southeast Kaiser Permanente
Atlanta, GA
USA

Antoine C. El Khoury

Director
Market Access and Health Economics
Johnson & Johnson Pharmaceutical
Horsham, PA
USA

Joel M. Gelfand

Associate Professor of Dermatology and Epidemiology
Center for Clinical
Epidemiology and Biostatistics

Center for Pharmacoepidemiology Research and Training
Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, PA
USA

Kate Gelperin

Medical Officer
Division of Epidemiology
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
US Food and Drug Administration
Silver Spring, MD
USA

Jason Glanz

Epidemiologist
Institute for Health Research
Kaiser Permanente Colorado
Department of Epidemiology Colorado
School of Public Health
Denver, CO
USA

Henry A. Glick

Professor of Medicine
Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, PA
USA

Robert Gross

Associate Professor of Medicine and Epidemiology
Center for Clinical Epidemiology and Biostatistics
Center for Pharmacoepidemiology Research and Training

Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, PA
USA

Gordon H. Guyatt

Professor
Department of Clinical Epidemiology and Biostatistics
McMaster University
Health Sciences Center
and
Department of Medicine
St Joseph's Hospital
Hamilton, Ontario
Canada

Katherine Haffner

Project Administrator
Harvard Pilgrim Health Care Institute
and
Department of Population Medicine
Harvard Medical School
Boston, MA
USA

Sean Hennessy

Associate Professor of Epidemiology
and of Pharmacology
Center for Clinical Epidemiology and Biostatistics
Director,
Center for Pharmacoepidemiology
Research and Training
Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, PA

USA

Ron M.C. Herings

Director

PHARMO Institute

Utrecht, The Netherlands

and

Associate Professor of

Pharmaceutical Technology Assessment

Erasmus University Rotterdam

Rotterdam, The Netherlands

Roman Jaeschke

Professor of Clinical Epidemiology and Biostatistics

McMaster University

Health Sciences Center

and

Professor of Medicine

St Joseph's Hospital

Hamilton, Ontario

Canada

Bradley C. Johnston

Assistant Professor of Clinical Epidemiology and Biostatistics

McMaster University

Hamilton, Ontario

and

Assistant Professor

Institute of Health Policy Management and Evaluation and

Department of Anesthesia & Pain Medicine, University of
Toronto

and

Scientist

The Hospital for Sick Children Research Institute

Toronto, Ontario

Canada

Judith K. Jones

President and CEO

The Degge Group Ltd

Arlington, VA

and

Adjunct Professor

Georgetown University

Washington, DC

USA

Jason Karlawish

Professor of Medicine

Perelman School of Medicine at the University of
Pennsylvania

Philadelphia, PA

USA

David W. Kaufman

Associate Director

Slone Epidemiology Center at Boston University

and

Professor of Epidemiology

Boston University School of Public Health

Boston, MA

USA

Aaron S. Kesselheim

Assistant Professor of Medicine

Division of Pharmacoepidemiology and Pharmacoeconomics

Brigham and Women's Hospital

Harvard Medical School

Boston, MA

USA

Stephen E. Kimmel

Professor of Medicine and Epidemiology
Center for Clinical
Epidemiology and Biostatistics
Center for Pharmacoepidemiology
Research and Training
Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, PA
USA

Karel Kostev

Senior Research Analyst
Centre of Excellence Patient Data
IMS Health GmbH & Co OHG
Frankfurt/Main, Germany

Sinéad M. Langan

NIHR Clinician Scientist
London School of Hygiene and Tropical Medicine
and
Honorary Consultant Dermatologist
St John's Institute of Dermatology
London, UK

David Lee

Director
Technical Strategy and Quality
Center for Pharmaceutical
Management
Management Sciences for Health, Inc.
Arlington, VA
USA

Samuel M. Lesko

Medical Director

Northeast Regional Cancer Institute
Scranton, PA

and

Adjunct Professor of Basic Sciences
The Commonwealth Medical College
Scranton, PA

and

Adjunct Professor of Public Health Sciences
Pennsylvania State University College of Medicine
Hershey, PA
USA

Hubert G. Leufkens

Professor of Pharmacoepidemiology and Clinical
Pharmacotherapy

Utrecht Institute for Pharmaceutical Sciences
Utrecht University
Utrecht, The Netherlands

Marie Lindquist

Director

Uppsala Monitoring Centre
WHO Collaborating Centre for International Drug Monitoring
Uppsala, Sweden

Helene Levens Lipton

Professor of Pharmacy and Health Policy
Schools of Medicine and Pharmacy
University of California at San
Francisco
San Francisco, CA
USA

Sumit R. Majumdar

Professor of Medicine
Faculty of Medicine and Dentistry

University of Alberta
Edmonton, Alberta
Canada

Claudia Manzo

Director
Division of Risk Management
Office of Surveillance and Epidemiology
Center for Drug Evaluation and Research
US Food and Drug Administration
Silver Spring, MD
USA

Danica Marinac-Dabic

Director
Division of Epidemiology
Office of Surveillance and Biometrics
Center for Devices and Radiological Health
US Food and Drug Administration
Silver Spring, MD
USA

Allen A. Mitchell

Director
Slone Epidemiology Center at Boston University
and
Professor of Epidemiology and Pediatrics
Boston University Schools of Public
Health and Medicine
Boston, MA
USA

Jingping Mo

Senior Director
Epidemiology
Worldwide Research & Development

Pfizer Inc.
New York, NY
USA

Yola Moride

Full Professor
Faculty of Pharmacy
Université de Montréal
and
Researcher
CHUM Research Center (CRCHUM)
Montreal, Quebec Canada

Sharon-Lise T. Normand

Professor of Health Care Policy
(Biostatistics)
Harvard Medical School
and
Professor of Biostatistics
Harvard School of Public Health
Boston, MA
USA

Alexis Ogdie

Instructor in Medicine
Division of Rheumatology
Center for Clinical Epidemiology and Biostatistics
Center for Pharmacoepidemiology
Research and Training
Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, PA
USA

Cristin Palumbo Freeman

Research Project Manager

Center for Clinical Epidemiology and Biostatistics
Center for Pharmacoepidemiology
Research and Training
Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, PA
USA

John Parkinson

Director
Clinical Practice Research Datalink (CPRD)
Medicines and Healthcare Products
Regulatory Agency (MHRA)
London, UK

Pamala A. Pawloski

HealthPartners Institute for Education and Research
Bloomington, MN
and
Adjunct Assistant Professor
University of Minnesota College of Pharmacy
Minneapolis, MN
USA

Lars Pedersen

Professor of Clinical
Epidemiology
Department of Clinical Epidemiology
Aarhus University Hospital
Aarhus, Denmark

Richard Platt

Professor and Chair
Department of Population Medicine, Harvard Medical School
and
Executive Director